心力衰竭与外周动脉疾病:达格列净在DAPA-HF和DELIVER试验中的患者水平荟萃分析
该研究对DAPA-HF和DELIVER试验进行患者水平汇总分析,评估达格列净在合并外周动脉疾病(PAD)的心衰患者中的疗效与安全性。结果显示,PAD患者主要终点和截肢风险均更高,但达格列净的获益与无PAD患者一致,且不增加截肢风险。
要点
- PAD患者主要终点发生率更高(15.1 vs 10.6/100人年),截肢风险也更高。
- 达格列净在合并与不合并PAD患者中均一致降低主要终点风险,交互作用P=0.39。
- 达格列净不增加截肢风险,即使PAD患者中截肢主要触发因素为感染而非缺血。
核心结论
- 合并PAD的心衰患者发生心衰恶化或心血管死亡的风险更高,截肢风险也更高。
- 达格列净在合并与不合并PAD的患者中获益一致,且不增加截肢风险。
研究设计与样本
- 对DAPA-HF和DELIVER试验进行患者水平汇总分析,评估达格列净在射血分数降低、轻度降低/保留的心衰患者中的疗效与安全性。
- 共纳入11 007例患者,其中11 005例有PAD病史数据;PAD患者809例(7.4%)。
- 中位随访22个月(四分位距17-30)。
主要发现
- PAD患者主要终点(心衰恶化或心血管死亡)发生率为15.1/100人年(95%CI 13.1-17.3),非PAD患者为10.6/100人年(95%CI 10.2-11.1);校正风险比1.23(95%CI 1.06-1.43)。
- 达格列净对主要终点的获益在PAD患者(HR 0.71,95%CI 0.54-0.94)和非PAD患者(HR 0.80,95%CI 0.73-0.88)中一致(交互作用P=0.39)。
- 截肢在PAD患者中更常见,但达格列净组与安慰剂组相比无差异(PAD:安慰剂4.2% vs 达格列净3.7%;无PAD:0.4% vs 0.4%;交互作用P=1.00)。
- 截肢的主要触发因素为感染而非缺血,即使在PAD患者中也是如此。
临床怎么用
- 对于合并PAD的心衰患者,达格列净的获益与无PAD患者一致,且不增加截肢风险,可考虑使用。
- PAD患者心衰恶化和截肢风险较高,应加强监测和综合管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Because an increased risk of amputation with canagliflozin was reported in the CANVAS trials, there has been a concern about the safety of sodium-glucose cotransporter 2 inhibitors in patients with peripheral artery disease (PAD) who are at higher risk of amputation. METHODS AND RESULTS: A patient-level pooled analysis of the DAPA-HF and DELIVER trials, which evaluated the efficacy and safety of dapagliflozin in patients with heart failure (HF) with reduced, mildly reduced/preserved ejection fraction, respectively, was conducted. In both trials, the primary outcome was the composite of worsening HF or cardiovascular death, and amputation was a prespecified safety outcome. Peripheral artery disease history was available for 11 005 of the total 11 007 patients. Peripheral artery disease was reported in 809 of the 11 005 patients (7.4%). Median follow-up was 22 months (interquartile range 17-30). The rate of the primary outcome (per 100 person-years) was higher in PAD patients than that in non-PAD patients: 15.1 [95% confidence interval (CI) 13.1-17.3) vs. 10.6 (10.2-11.1]; adjusted hazard ratio 1.23 (95% CI 1.06-1.43). The benefit of dapagliflozin on the primary outcome was consistent in patients with [hazard ratio 0.71 (95% CI 0.54-0.94)] and without PAD [0.80 (95% CI 0.73-0.88)] (Pinteraction = 0.39). Amputations, while more frequent in PAD patients, were not more common with dapagliflozin, compared with placebo, irrespective of PAD status (PAD, placebo 4.2% vs. dapagliflozin 3.7%; no PAD, placebo 0.4% vs. dapagliflozin 0.4%) (Pinteraction = 1.00). Infection rather than ischaemia was the main trigger for amputation, even in patients with PAD. CONCLUSION: The risk of worsening HF or cardiovascular death was higher in patients with PAD, as was the risk of amputation. The benefits of dapagliflozin were consistent in patients with and without PAD, and dapagliflozin did not increase the risk of amputation.
引用
- Butt, Kondo, Yang, et al. Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. Eur Heart J. 2023. PMID: 37220172. doi:10.1093/eurheartj/ehad276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。